MaxCyte (LON:MXCT) Reaches New 12-Month Low - Here's Why

MaxCyte, Inc. (LON:MXCT - Get Free Report)'s stock price reached a new 52-week low during trading on Thursday . The stock traded as low as GBX 155.50 ($2.09) and last traded at GBX 160 ($2.15), with a volume of 31853 shares changing hands. The stock had previously closed at GBX 161.10 ($2.16).

MaxCyte Trading Down 0.7%

The firm has a fifty day moving average of GBX 180.71 and a 200 day moving average of GBX 261.69. The firm has a market capitalization of £211.21 million, a PE ratio of -5.86 and a beta of 1.13. The company has a debt-to-equity ratio of 8.59, a quick ratio of 14.38 and a current ratio of 9.81.

MaxCyte Company Profile

MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.